Abstracts tagged "autoimmunity and systemic lupus erythematosus (SLE)"

Abstract Number: 2128 • 2018 ACR/ARHP Annual Meeting
The Effect of miRNA-21 Overexpression on the Aberrant T Follicular Helper Cells Differentiation in Systemic Lupus Erythematosus
Ming Zhao¹, Xiaofei Gao², Jiali Wu³, Limin Liu¹, Haijing Wu² and Qianjin Lu¹, ¹Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China, ²The Second Xiangya Hospital of Central South University, Changsha, China, ³Department of Deramtology, The Second Xiangya Hospital of Central South University, Changsha, China
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that is characterized by a large number of autoantibodies and multiple organs damage. T follicular helper(Tfh)…
Abstract Number: 901 • 2017 ACR/ARHP Annual Meeting
Role of Epstein Barr Virus Serologic Reactivation in Transitioning to Systemic Lupus Erythematosus in at Risk Individuals
Neelakshi R. Jog¹, Kendra A. Young², Melissa E. Munroe¹, Michael T Harmon³, Joel M. Guthridge⁴, Diane L. Kamen⁵, Gary S. Gilkeson⁶, Michael Weisman⁷, David Karp⁸, John B. Harley^9,10, Daniel J. Wallace¹¹, Jill M. Norris¹² and Judith A. James^13,14, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, OKC, OK, ⁵Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁶Department of Medicine, Medical University of South Carolina, Charleston, SC, ⁷Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Rheumatology, UT Southwestern Med Ctr, Dallas, TX, ⁹US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹⁰Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹¹Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹²Department of Epidemiology, Colorado School of Public Health, Aurora, CO, ¹³Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease characterized by autoantibody production and periods of elevated and suppressed disease activity. Various genetic and…
Abstract Number: 2640 • 2017 ACR/ARHP Annual Meeting
Response Gene to Complement-32 Expression Is Upregulated in Lupus T Cells and Promotes IL-17A Expression
Vinh Nguyen¹, Alexandru Tatomir², Cornelia Cudrici³, Horea Rus² and Violeta Rus¹, ¹Medicine, University of Maryland School of Medicine and Veteran Affairs Medical Center, Baltimore, MD, ²Neurology, University of Maryland School of Medicine and Veteran Affairs Medical Center, Baltimore, MD, ³NIAMS, NIAMS, NIH, Bethesda, MD
Background/Purpose: RGC (Response Gene to Complement)-32 is a cell cycle regulator widely expressed in normal tissues including brain, kidney, spleen, thymus, multiple tumors and in…
Abstract Number: 2647 • 2017 ACR/ARHP Annual Meeting
Epstein Barr Virus Interluekin-10 (vIL10) in Systemic Lupus Erythematosus
Neelakshi R. Jog¹, Eliza Chakravarty¹, Joel M. Guthridge² and Judith A. James^3,4, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease characterized by autoantibody production and periods of elevated and suppressed disease activity. Various genetic and…
Abstract Number: 1803 • 2016 ACR/ARHP Annual Meeting
General Features of SLE Patients Presenting with Autoimmune Hemolytic Anemia
Regaip Elezi¹, Gulsum Emel Pamuk², Muhammet Maden², Mehmet Ali Balci^1,3 and Omer Nuri Pamuk¹, ¹Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, ²Hematology, Trakya University Medical Faculty, Edirne, Turkey, ³Department of Rheumatology, Trakya University Medical Faculty, Edirne, Turkey
Background/Purpose: Anemia in systemic lupus erythematosus (SLE) might have various etiologies; however, autoimmune hemolytic anemia (AIHA) is the characteristic hematologic feature. AIHA might be primary…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].